PTO/SB/08b(11-07) Approved for use through 11/30/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

	Substitute for form 1449B/PTO				Complete if Known		
	INITOT	ON A TION	DIC	OL OCUPE	Application Number	10/729,387	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT					Filing Date	December 8, 2003	
	STATI	EMENT B	YΑ	PPLICANT	First Named Inventor	Francis J. GILES, et al.	
					Art Unit	1614	
(Use as many sheets as necessary)					Examiner Name	James D. Anderson	
<u> </u>	Sheet	1	of	1	Attorney Docket Number	STROMIX-0007	

NON PATENT LITERATURE DOCUMENTS								
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, dity and/or country where published.	T²					
/JDA/		TYLER, J., et al. "Efficacy of STI571, an Abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against Bcr-Abl-positive cells" BLOOD, 96(9):3195-3199. November 1, 2009.						

Examiner Signature	/James Anderson/	Date Considered	10/14/2010	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

and not considered. Include copy dates the minimum conformation to applicant.

Applicant is unjust called a possible to minimum conformation to applicant.

Applicant is unjust called minimum conformation to applicant.

Applicant is unjust called minimum conformation at many called a possible to the minimum conformation at technical called a possible to the minimum conformation is required by 37 CPR 1.98. The information is required by 47 CPR 1.98. The information is required by 48 CPR 1.98. The inform ner curry to by Ducessy air spinearum. Commentantly signed on the Curry Learner of verification in the USPTO. This make will vary depending and submitting the completed application from to the USPTO. This will vary depending non the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief information Officer, U.S. Patent and Trademark Office. U.S. Department of Commence, P.O., Box 1450, Mexandriq, X.P. 28213-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.